Result Number | Material Type | Add to My Shelf Action | Record Details and Options |
---|---|---|---|
1 |
Material Type: Article
|
Randomized Controlled Trial of Febuxostat Versus Allopurinol or Placebo in Individuals with Higher Urinary Uric Acid Excretion and Calcium StonesClinical journal of the American Society of Nephrology, 2013-11, Vol.8 (11), p.1960-1967 [Peer Reviewed Journal]Copyright © 2013 by the American Society of Nephrology 2013 ;ISSN: 1555-9041 ;EISSN: 1555-905X ;DOI: 10.2215/CJN.01760213 ;PMID: 23929928Full text available |
|
2 |
Material Type: Article
|
Effect of Febuxostat on Ambulatory Blood Pressure in Subjects With Hyperuricemia and Hypertension: A Phase 2 Randomized Placebo‐Controlled StudyJournal of the American Heart Association, 2017-11, Vol.6 (11), p.n/a [Peer Reviewed Journal]2017 The Authors and Takeda Pharmaceuticals. Published on behalf of the American Heart Association, Inc., by Wiley. ;ISSN: 2047-9980 ;EISSN: 2047-9980 ;DOI: 10.1161/JAHA.117.006683 ;PMID: 29102979Full text available |
|
3 |
Material Type: Article
|
Efficacy and safety of febuxostat extended release and immediate release in patients with gout and moderate renal impairment: phase II placebo-controlled studyArthritis research & therapy, 2018-05, Vol.20 (1), p.99-99, Article 99 [Peer Reviewed Journal]COPYRIGHT 2018 BioMed Central Ltd. ;Copyright © 2018. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and conditions, you may use this content in accordance with the terms of the License. ;The Author(s). 2018 ;ISSN: 1478-6362 ;ISSN: 1478-6354 ;EISSN: 1478-6362 ;DOI: 10.1186/s13075-018-1593-0 ;PMID: 29848361Full text available |
|
4 |
Material Type: Article
|
The Impact of Label Changes (Boxed Warning) on Real-World Febuxostat Utilization in Patients with Gout: A Cross-Sectional Drug Utilization StudyRheumatology and therapy., 2023-10, Vol.10 (5), p.1277-1295 [Peer Reviewed Journal]The Author(s) 2023 ;2023. The Author(s). ;ISSN: 2198-6576 ;EISSN: 2198-6584 ;DOI: 10.1007/s40744-023-00581-x ;PMID: 37460856Full text available |
|
5 |
Material Type: Article
|
ReplyArthritis & rheumatology (Hoboken, N.J.), 2016-10, Vol.68 (10), p.2564-2564 [Peer Reviewed Journal]2016, American College of Rheumatology ;ISSN: 2326-5191 ;EISSN: 2326-5205 ;DOI: 10.1002/art.39768Full text available |
|
6 |
Material Type: Article
|
ReplyArthritis & rheumatology (Hoboken, N.J.), 2016-10, Vol.68 (10), p.2564-2564 [Peer Reviewed Journal]ISSN: 2326-5191 ;EISSN: 2326-5205 ;DOI: 10.1002/art.39768Full text available |
|
7 |
Material Type: Article
|
ReplyArthritis & rheumatology (Hoboken, N.J.), 2016-10, Vol.68 (10), p.2564 [Peer Reviewed Journal]2016, American College of Rheumatology ;ISSN: 2326-5191 ;EISSN: 2326-5205 ;DOI: 10.1002/art.39768Full text available |
|
8 |
Material Type: Article
|
Cardiovascular Safety of Febuxostat or Allopurinol in Patients with GoutThe New England journal of medicine, 2018-03, Vol.378 (13), p.1200-1210 [Peer Reviewed Journal]Copyright © 2018 Massachusetts Medical Society. All rights reserved. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1710895 ;PMID: 29527974Full text available |
|
9 |
Material Type: Article
|
Impact of Febuxostat on Renal Function in Gout Patients With Moderate‐to‐Severe Renal ImpairmentArthritis & rheumatology (Hoboken, N.J.), 2016-08, Vol.68 (8), p.2035-2043 [Peer Reviewed Journal]2016, American College of Rheumatology ;2016, American College of Rheumatology. ;ISSN: 2326-5191 ;EISSN: 2326-5205 ;DOI: 10.1002/art.39654 ;PMID: 26894653Full text available |
|
10 |
Material Type: Article
|
ReplyArthritis & rheumatology (Hoboken, N.J.), 2016-10, Vol.68 (10), p.2564-2564 [Peer Reviewed Journal]EISSN: 2326-5205 ;DOI: 10.1002/art.39768Full text available |
|
11 |
Material Type: Article
|
ReplyArthritis & rheumatology (Hoboken, N.J.), 2016-10, Vol.68 (10), p.2564 [Peer Reviewed Journal]EISSN: 2326-5205 ;PMID: 27273789Full text available |
|
12 |
Material Type: Article
|
A Long-Term, Open-Label Safety and Tolerability Study of Lisdexamfetamine Dimesylate in Children Aged 4-5 Years with Attention-Deficit/Hyperactivity DisorderJournal of child and adolescent psychopharmacology, 2022-03, Vol.32 (2), p.98-106 [Peer Reviewed Journal]Copyright Mary Ann Liebert, Inc. Mar 2022 ;Ann C. Childress et al. 2022; Published by Mary Ann Liebert, Inc. 2022 Ann C. Childress et al. ;ISSN: 1044-5463 ;EISSN: 1557-8992 ;DOI: 10.1089/cap.2021.0138 ;PMID: 35230142Full text available |
|
13 |
Material Type: Article
|
Cardiovascular Safety of FebuxostatThe New England journal of medicine, 2018-10, Vol.379 (16), p.1582-1584 [Peer Reviewed Journal]Copyright © 2018 Massachusetts Medical Society. All rights reserved. ;ISSN: 0028-4793 ;ISSN: 1533-4406 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMc1809736 ;PMID: 30332566Full text available |
|
14 |
Material Type: Patent
|
METHODS FOR CONCOMITANT TREATMENT OF THEOPHYLLINE AND FEBUXOSTATDigital Resources/Online E-Resources |
|
15 |
Material Type: Article
|
The effects of xanthine oxidase inhibition by febuxostat on the pharmacokinetics of theophyllineInternational journal of clinical pharmacology and therapeutics, 2012-05, Vol.50 (5), p.331-337 [Peer Reviewed Journal]ISSN: 0946-1965 ;DOI: 10.5414/CP201648 ;PMID: 22541837Full text available |
|
16 |
Material Type: Patent
|
Methods of treatment and compositions with xanthine oxidase inhibitorsDigital Resources/Online E-Resources |
|
17 |
Material Type: Article
|
Drug Interaction Studies with Dexlansoprazole Modified Release (TAK-390MR), a Proton Pump Inhibitor with a Dual Delayed-Release Formulation: Results of Four Randomized, Double-Blind, Crossover, Placebo-Controlled, Single-Centre StudiesClinical drug investigation, 2009, Vol.29 (1), p.35-50 [Peer Reviewed Journal]Adis Data Information BV 2009 ;Copyright Wolters Kluwer Health Adis International 2009 ;ISSN: 1173-2563 ;EISSN: 1179-1918 ;DOI: 10.2165/0044011-200929010-00004 ;PMID: 19067473Full text available |
|
18 |
Material Type: Patent
|
Methods for concomitant treatment of theophylline and febuxostatDigital Resources/Online E-Resources |
|
19 |
Material Type: Patent
|
Methods of treatment and compositions with xanthine oxidase inhibitorsDigital Resources/Online E-Resources |
|
20 |
Material Type: Patent
|
METHODS FOR CONCOMITANT TREATMENT OF THEOPHYLLINE AND FEBUXOSTATDigital Resources/Online E-Resources |